Current recommendations for revascularization of non-infarct-related artery in patients presenting with ST-segment elevation myocardial infarction and multivessel disease

被引:2
|
作者
Towashiraporn, Korakoth [1 ]
机构
[1] Mahidol Univ, Fac Med Siriraj Hosp, Her Majesty Cardiac Ctr, Bangkok, Thailand
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
关键词
ST-segment elevation myocardial infarction; multivessel disease; complete revascularization; percutaneous coronary intervention; infarct-related artery; PERCUTANEOUS CORONARY INTERVENTION; LESION-ONLY REVASCULARIZATION; CARDIOGENIC-SHOCK; SCIENTIFIC STATEMENT; RANDOMIZED-TRIAL; CULPRIT LESION; MANAGEMENT; PLAQUE; STEMI; OUTCOMES;
D O I
10.3389/fcvm.2022.969060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ST-segment elevation myocardial infarction (STEMI) is a leading cause of morbidity and mortality worldwide. Immediate reperfusion therapy of the infarct-related artery (IRA) is the mainstay of treatment, either via primary percutaneous coronary intervention (PPCI) or thrombolytic therapy when PPCI is not feasible. Several studies have reported the incidence of multivessel disease (MVD) to be about 50% of total STEMI cases. This means that after successful PPCI of the IRA, residual lesion(s) of the non-IRA may persist. Unlike the atherosclerotic plaque of stable coronary artery disease, the residual obstructive lesion of the non-IRA contains a significantly higher prevalence of vulnerable plaques. Since these lesions are a strong predictor of acute coronary syndrome, if left untreated they are a possible cause of future adverse cardiovascular events. Percutaneous coronary intervention (PCI) of the obstructive lesion of the non-IRA to achieve complete revascularization (CR) is therefore preferable. Several major randomized controlled trials (RCTs) and meta-analyses demonstrated the clinical benefits of the CR strategy in the setting of STEMI with MVD, not only for enhancing survival but also for reducing unplanned revascularization. The CR strategy is now supported by recently published clinical practice guidelines. Nevertheless, the benefit of revascularization must be weighed against the risks from additional procedures.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] The effect of complete revascularization in patients with ST-segment elevation myocardial infarction with Killip class ≥ III
    Lee, Wei-Chieh
    Chen, Tien-Yu
    Chen, Chien-Jen
    Yang, Cheng-Hsu
    Fang, Chih-Yuan
    Wu, Chiung-Jen
    Fang, Hsiu-Yu
    CORONARY ARTERY DISEASE, 2020, 31 (01) : 13 - 19
  • [42] The Inhibition of Evolocumab on Non-Infarct-Related Artery Disease in Patients with ST-Elevation Myocardial Infarction
    Zhao, Qi
    Sun, Siyuan
    Zhou, Fanghui
    Yue, Jingkun
    Luo, Xing
    Qu, Xiufen
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 2771 - 2781
  • [43] Management of Multivessel Coronary Disease in ST-segment Elevation Myocardial Infarction
    Banning, Amerjeet S.
    Gershlick, Anthony H.
    CURRENT CARDIOLOGY REPORTS, 2015, 17 (09)
  • [44] Complete revascularization for patients with multivessel coronary artery disease and ST-segment elevation myocardial infarction after the COMPLETE trial: A meta-analysis of randomized controlled trials
    Bajraktari, Gani
    Bytyci, Ibadete
    Henein, Michael Y.
    Alfonso, Fernando
    Ahmed, Ali
    Jashari, Haki
    Bhatt, Deepak L.
    IJC HEART & VASCULATURE, 2020, 29
  • [45] Immediate complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease treated by primary percutaneous coronary intervention: Insights from the ORBI registry
    Pimor, Anna
    Auffret, Vincent
    Didier, Romain
    Delaunay, Regis
    Filippi, Emmanuelle
    Hacot, Jean-Philippe
    Saouli, Djamel
    Rouault, Gilles
    Druelles, Philippe
    Bot, Emilie
    Coudert, Isabelle
    Boulanger, Bertrand
    Le Guellec, Marielle
    Boulmier, Dominique
    Leurent, Guillaume
    Bedossa, Marc
    Gilard, Martine
    Le Breton, Herve
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2018, 111 (11) : 656 - 665
  • [46] Revascularization in Patients With Spontaneous Coronary Artery Dissection and ST-Segment Elevation Myocardial Infarction
    Lobo, Angie S.
    Cantu, Stephanie M.
    Sharkey, Scott W.
    Grey, Elizabeth Z.
    Storey, Katelyn
    Witt, Dawn
    Benson, Gretchen
    Garberich, Ross F.
    Kubota, Yasuhiko
    Merz, C. Noel Bairey
    Henry, Timothy D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (10) : 1290 - 1300
  • [47] Optimal timing of staged percutaneous coronary intervention in ST-segment elevation myocardial infarction patients with multivessel disease
    Zhao, Xue-Dong
    Zhao, Guan-Qi
    Wang, Xiao
    Shi, Shu-Tian
    Zheng, Wen
    Guo, Rui-Feng
    Nie, Shao-Ping
    JOURNAL OF GERIATRIC CARDIOLOGY, 2018, 15 (05) : 356 - 362
  • [48] Serum apelin predicts spontaneous reperfusion of infarct-related artery in patients with ST-segment elevation myocardial infarction
    Zhou Ying
    Yuan Jiansong
    Wang Yong
    Qiao Shubin
    CORONARY ARTERY DISEASE, 2019, 30 (02) : 103 - 108
  • [49] The long-term impact of a chronic total occlusion in a non-infarct-related artery on acute ST-segment elevation myocardial infarction after primary coronary intervention
    Liu, Yu
    Wang, Le-Feng
    Yang, Xin-Chun
    Lu, Chang-Lin
    Li, Kui-Bao
    Chen, Mu-Lei
    Li, Na
    Wang, Hong-Shi
    Zhong, Jiu-Chang
    Xu, Li
    Ni, Zhu-Hua
    Li, Wei-Ming
    Xia, Kun
    Zhang, Da-Peng
    Sun, Hao
    Guo, Zong-Sheng
    Chi, Yong-Hui
    He, Ji-Fang
    Zhang, Zhi-Yong
    Jiang, Feng
    Wang, Hong-Jiang
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [50] The optimal timing for intervention in patients with ST-segment elevation myocardial infarction and multivessel disease: a systematic review and meta-analysis
    Chen, Yi
    Li, Meng
    Wu, Yanqing
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11